Sign Up to like & get
recommendations!
0
Published in 2020 at "Pharmacological research"
DOI: 10.1016/j.phrs.2020.104800
Abstract: The HBV-initiated hepatocellular carcinoma (HCC) frequently develops from or accompanies long-term chronic hepatitis, inflammation, and cirrhosis, and has a poor prognosis. Sorafenib, an orally active multi-kinase inhibitor, currently the most common approved drug for first-line…
read more here.
Keywords:
hepatocellular carcinoma;
ccl22 signaling;
ccl22;
sorafenib resistance ... See more keywords